PRESS RELEASE For immediate release DEVONIAN HEALTH GROUP INC. TO PARTICIPATE IN THREE RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES. QUEBEC, October 24, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical...
Press Releases
DEVONIAN TO PRESENT THYKAMINE™ PHASE 2 CLINICAL RESULTS AT THE 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR IINFLAMMATORY SKIN DISEASES
PRESS RELEASE For immediate release DEVONIAN TO PRESENT THYKAMINE™ PHASE 2 CLINICAL RESULTS AT THE 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR IINFLAMMATORY SKIN DISEASES. QUEBEC, October 12, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”)...
Devonian Health Group Announces Peer-reviewed publication of Thykamine™ positive phase 2 clinical trial results in Journal of Drugs in Dermatology
PRESS RELEASE For immediate release Devonian Health Group Announces Peer-reviewed publication of Thykamine™ positive phase 2 clinical trial results in Journal of Drugs in Dermatology. Clinical Study demonstrated dual benefit mode of action of Thykamine™ in...
DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS
PRESS RELEASE For immediate release DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS . QUEBEC, September 7, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage...
DEVONIAN ANNOUNCES EXECUTIVE CHANGES, GRANT OF STOCK OPTIONS AND SETTLEMENT OF INTERESTS AND REPAYMENT OF PRINCIPAL AMOUNT OWED TO A DEBENTURE HOLDER
PRESS RELEASE For immediate release DEVONIAN ANNOUNCES EXECUTIVE CHANGES, GRANT OF STOCK OPTIONS AND SETTLEMENT OF INTERESTS AND REPAYMENT OF PRINCIPAL AMOUNT OWED TO A DEBENTURE HOLDER. Executive changes announced in support of the Corporation Growth Phase: Ms. Sybil...
Devonian Health Group Announces the Journal of Drugs in Dermatology acceptance for publication of Thykamine™ positive phase 2 clinical trial results in Atopic Dermatitis
PRESS RELEASE For immediate release Devonian Health Group Announces the Journal of Drugs in Dermatology acceptance for publication of Thykamine™ positive phase 2 clinical trial results in Atopic Dermatitis. QUEBEC, May 26, 2022 – Devonian Health Group Inc....
Devonian Announces Adoption of Restricted Share Unit Plan
PRESS RELEASE For immediate release Devonian Announces Adoption of Restricted Share Unit Plan. QUEBEC, March 17th, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD ; OTCQB : DVHGF), a clinical stage botanical pharmaceutical...
Devonian Health Group Announces trading on the OTCQB® Market under symbol DVHGF
PRESS RELEASE For immediate release Devonian Health Group Announces trading on the OTCQB® Market under symbol DVHGF. QUEBEC, March 10, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical...
DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS
PRESS RELEASE For immediate release DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS. QUEBEC, March 7, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical...
Devonian Health Group Announces voting results of the Annual General and Special Meeting and welcome new board members
PRESS RELEASE For immediate release Devonian Health Group Announces voting results of the Annual General and Special Meeting and welcome new board members. QUEBEC, – March 1st , 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a...